China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN). The agreement entails providing contract development and manufacturing services for AstraZeneca’s mRNA vaccine, with no financial details disclosed.
Focus on mRNA Production Platform and Vaccine R&D
This strategic cooperation will leverage CanSino’s mRNA production platform to support AstraZeneca’s research and development of specific vaccines. The agreement period is set from August 7, 2023, to the corresponding date or the expiration date of the effective product supply plan after the tenth anniversary.
CanSino’s mRNA Technology Platform and Its Advantages
CanSino’s mRNA technology platform, which has been independently designed and developed, includes sequence optimization software that can identify key sites affecting stability and determine the optimal sequence for effectively improving antigen expression. The company’s CMC process is streamlined, allowing for a reduction in product development time and the rapid commercialization of scientific research results.
Progress in mRNA Vaccine Production Base Project
CanSino has made significant strips in completing the first phase of its mRNA vaccine production base project, which is crucial for supporting the development and commercialization of mRNA platform based products. This infrastructure will play a key role in fulfilling the objectives of the cooperation agreement and meeting the growing demand for mRNA vaccine solutions.-Fineline Info & Tech
